Anti-HBV (hepatitis B virus) [Hepatitis B virus] therapeutic antibody (Pre-made Tuvirumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tuvirumab is a human monoclonal antibody for the treatment of patients with chronic hepatitis B. It has undergone Phase I clinical trials in 21.[1][2]